Merck Stock: Has Market Overvalued Future Growth?
Merck's stock has been on a tear, climbing +84% over the last twelve months and outperforming its peers. However, its underlying business results are less impressive, with the company's revenue growth of 4.6% placing it fourth in its group and its operating margin ranking dead last among its competitors.
The market is rewarding Merck for its pipeline of future products, which management claims has a potential commercial value of over $70 billion. The recent FDA approval of LIPFENDRA, an oral PCSK9 inhibitor for high cholesterol, has added to the optimism surrounding the stock.
However, the company's ability to execute on this vision remains uncertain, and analysts have expressed concerns about the transition away from KEYTRUDA, Merck's top-selling cancer treatment. The launch of LIPFENDRA is seen as a key test of Merck's commercial capabilities, and its early adoption and sales trajectory will be closely watched by investors.
The question remains whether the market has correctly priced in a post-KEYTRUDA future for Merck, or if the stock's stellar run was premature. The answer to this question will depend on the company's ability to deliver on its pipeline promise and convert it into financial reality.